Diabetes Mellitus Clinical Trial
Official title:
Neurocognitive and Neuroanatomical Studies in Young Children With Type 1 Diabetes Mellitus
| Verified date | April 2016 |
| Source | Stanford University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Observational |
Simplified Brochure
Neuropsychological Testing/Assessment is like games for the child. They are asked to
complete the sequence, identify pictures, explain what is happening, etc. There is no
personality testing involved. Part of the standard IQ testing is done but no IQ score is
obtained. Age appropriate testing is done for each child.
The MRI is an enclosed machine. We have the child sit in a simulator after the
neuropsychological testing to see what it will be like, including the sounds, etc. You will
be given a video about MRI testing to view as well. The staff that does this has been doing
this for years in a wide variety of children, young, developmental delayed, etc. The staff
does this WITHOUT sedation. Some children cannot sit still through the entire series. We
need to get six, 10 minute scans. Children are allowed movement such as the need to wiggle
their toes and move in between each scan.
The Neuropsychological Testing can be scheduled in the late afternoons if it is more
convenient for your family. This visit may take 3-4 hours. The MRI scanning can be scheduled
after 5pm and may take up to 2 hours depending on the child's cooperation. You maybe asked
to repeat the Neuropsychological Testing and MRI scanning 24 months later.
| Status | Completed |
| Enrollment | 43 |
| Est. completion date | December 2015 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 3 Years to 10 Years |
| Eligibility |
Inclusion Criteria: - To take part in the study, you or your child must meet the following inclusion criteria: - Be between the ages of 3 to 10 years. - Have been diagnosed with type 1 diabetes for at least 6 months. - Do not have plans to move out of the area within the next 36 months. Exclusion Criteria: If the interested participant has a history of: - head trauma with any loss of consciousness, - cystic fibrosis, - prematurity (born less than 30 weeks of gestation), - significant developmental delay (lack of single word speech or ability to walk independently by 18 months of age), - neurologic disease independent of diabetes (eg seizure disorder or medical contraindication to MRI procedure (eg metal appliances such as braces) |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| United States | Stanford University School of Medicine | Stanford | California |
| Lead Sponsor | Collaborator |
|---|---|
| Stanford University | William E And Aenid R Weisgerber Foundation |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | MRI brain volumes | 3 years | No | |
| Secondary | Neuropsychological scores | FSIQ, Memory score, Verbal comprehension score | 3 yr | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |